



**501-3292 Production Way, Burnaby, B.C., V5A 4R4**

**Phone: (604) 551-7831    Fax: 604-676-2767**

**[info@cannabixtechnologies.com](mailto:info@cannabixtechnologies.com)**

**[cannabixtechnologies.com](http://cannabixtechnologies.com)**

## **Cannabix Technologies Adds Dr. Randall Purves as Scientific Advisor**

*The Cannabix Marijuana Breathalyzer system is being developed to give law enforcement and employers a tool to enforce public safety.*

Vancouver, British Columbia, May 13, 2019 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company”) is pleased to announce that Dr. Randy Purves has been appointed as a Scientific Advisor to Cannabix Technologies Inc. Dr. Purves is one of the world’s foremost experts in the development of FAIMS (high-field asymmetric waveform ion mobility spectrometry) instrumentation and applications. Dr. Purves is a pioneer in developing FAIMS technology and in 2001 he co-founded Ionalytics, an instrument company specializing in FAIMS devices for use with mass spectrometry. Ionalytics was acquired by Thermo Electron (now Thermo Fisher Scientific) in 2005 and Dr. Purves was part of the Thermo team involved with the commercial release of an integrated FAIMS product for use with a TSQ Quantum mass spectrometer in 2006.

Dr. Randy Purves obtained his Ph.D. in Analytical Chemistry from the University of Alberta. Dr. Purves has over 25 years of experience working with mass spectrometry, which includes working in drug metabolism at Merck Frosst. Dr. Purves is an expert in the development and application of FAIMS, having co-authored 45 refereed publications in FAIMS and differential mobility spectrometry (DMS) in general. Dr. Purves is an adjunct professor in the College of Pharmacy and Nutrition at the University of Saskatchewan and continues to collaborate with Thermo Fisher Scientific on further enhancing FAIMS technology for mass spectrometry based applications. A primary interest of Dr. Purves is to use his expertise in FAIMS and small molecule analysis to improve quantification methods of analytes in challenging matrices.

Dr. Raj Attariwala, Cannabix’s Chief Scientific Officer, states, “Dr. Purves has deep, unparalleled experience with FAIMS technology that will be a tremendous benefit to our scientific team and technology development.”

The Company has granted Dr. Purves 150,000 stock options exercisable at \$1.50 for a period of 2 years.

### **About Cannabix Technologies Inc.**

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects previous usage from days or even weeks earlier. The devices will also be useful for other practical applications such as testing

employees in the workplace where impairment by THC can be hazardous.

We seek Safe Harbor.

*On behalf of the Board of Directors*

“Rav Mlait”

CEO  
Cannabix Technologies Inc.

For further information, contact the Company at [info@cannabixtechnologies.com](mailto:info@cannabixtechnologies.com)

*The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.*

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing "patent pending" technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.